Estrella Immunopharma, Inc.
ESLAW
NASDAQ Capital Market0.13
USD
-0.01
- -
Estrella Immunopharma, Inc.
ESLAW
(NASDAQ Capital Market)
Recent
price
0.13
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Estrella Immunopharma, Inc. operates as a clinical-stage biopharmaceutical company, dedicated to developing advanced T-cell therapies for various cancers and autoimmune conditions within the United States. The company's pipeline features lead candidates such as EB103, a CD19-directed ARTEMIS® T-cell therapy currently undergoing Phase I/II clinical trials for the treatment of advanced B-cell non-Hodgkin's lymphoma. Recent findings from the STARLIGHT-1 trial's second dose cohort revealed a 100% complete response rate in all evaluable patients at the one-month mark, including high-risk individuals often excluded from conventional CD19 treatments. Another key program is EB104, engineered to target both CD19 and CD22 proteins, aiming to address B-cell malignancies and acute lymphocytic leukemia. Estrella employs its unique ARTEMIS® platform technology, licensed from its parent company Eureka Therapeutics, which is designed to enhance T-cell activation and regulation, mitigating severe toxicities like cytokine release syndrome often associated with earlier CAR-T therapies. Additionally, the company is engaged in a strategic collaboration with Imugene Limited, utilizing Imugene's oncolytic virus product candidate, CF33-CD19t, in conjunction with EB103 to implement a "Mark and Kill" strategy for solid tumors that typically lack inherent targets. Headquartered in Emeryville, California, Estrella Immunopharma continues to advance its therapeutic initiatives, recently expanding its STARLIGHT-1 trial to include an additional clinical site at Baylor Research Institute and regaining compliance with Nasdaq listing standards.
Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLAW) Expands By 54.2%
Estrella Immunopharma, Inc. (NASDAQ:ESLAW) Short Interest Up 189.0% in January